Severe neutropenia after rituximab-treatment of multiple sclerosis

Mult Scler Relat Disord. 2018 Feb:20:3-5. doi: 10.1016/j.msard.2017.12.005. Epub 2017 Dec 12.

Abstract

We present here the first MS-case where rituximab-treatment led to grade IV neutropenia, with hospitalization and treatment of a serious infection with broad-spectrum antibiotics. The neutropenia resolved promptly with granulocyte-colony stimulating factor-treatment and the patient recovered well. Due to risk of recurring neutropenia rituximab-treatment was not re-administered. We discuss the mechanisms and occurrence of neutropenia as a side effect to rituximab-treatment of MS, and remind of the importance of monitoring rituximab-treated MS-patients for this rare but potentially dangerous side effect.

Keywords: Granulocytopenia; Multiple sclerosis; Neutropenia; Rituximab.

Publication types

  • Case Reports

MeSH terms

  • Diagnosis, Differential
  • Humans
  • Immunologic Factors / adverse effects*
  • Immunologic Factors / therapeutic use
  • Male
  • Multiple Sclerosis / drug therapy*
  • Neutropenia / etiology*
  • Neutropenia / physiopathology
  • Neutropenia / therapy
  • Rituximab / adverse effects*
  • Rituximab / therapeutic use
  • Young Adult

Substances

  • Immunologic Factors
  • Rituximab